Karen A. Dawes
Director · Barinthus Biotherapeutics plc.
IndividualSelling only
- 2025
- Sep 9, 2026
- 5
Other insiders active in the same sector
No other insider has filed at Karen A. Dawes's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- L1 Capital Pty Ltd - $72.66M in AVR purchases and sales in the last 12 months
- James E. Flynn - $70.87M in NUVL purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $69.43M in VOR purchases and sales in the last 12 months
- Joaquin Duato - $66.84M in JNJ purchases and sales in the last 12 months
- Eric Venker - $65.62M in ROIV purchases and sales in the last 12 months
- EcoR1 Capital, LLC - $65.00M in TRAX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Karen A. Dawes?
Karen A. Dawes is a corporate insider, tracked as Director of Barinthus Biotherapeutics plc. (BRNS). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Karen A. Dawes submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Karen A. Dawes been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($44K) across all tracked filings.
